NCT03934814: Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

NCT03934814
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase (Part 1)
Exclusions: Patients with known symptomatic central nervous system metastases or leptomeningeal disease requiring steroids; Patients with prior treatment of CD47, SIRPa inhibitors, or CAR T-cell therapy
https://ClinicalTrials.gov/show/NCT03934814

Comments are closed.

Up ↑